BRD1: A Potential Drug Target and Biomarker for Breast Cancer

Target Name: BRD1

NCBI ID: G23774

BRD1: A Potential Drug Target and Biomarker for Breast Cancer

BRD1 (Breast and calamine-like molecule 1) is a gene that encodes a protein known as BRD1-ALZH2, which is a key regulator of cell growth and differentiation. The BRD1 gene has been implicated in the development and progression of many diseases, including breast cancer, and is a potential drug target for breast cancer.

BRD1-ALZH2 is a transmembrane protein that plays a critical role in regulating cell proliferation and survival. It is expressed in almost all human tissues and is involved in various cellular processes, including cell adhesion, migration, and angiogenesis. The protein is composed of two isoforms, ALZH2 and BRD1, which are expressed in different cell types and have distinct functions.

BRD1 is a transcription factor that regulates the expression of genes involved in cell growth and differentiation. It is a critical regulator of the TGF-β pathway, which is involved in cell proliferation, differentiation, and survival. The TGF-β pathway is a well -established target for many diseases, including breast cancer, and it is possible that BRD1 may be a drug target for this disease.

BRD1 has also been implicated in the development of many other diseases, including cancer, neurodegenerative diseases, and autoimmune diseases. It is a potential biomarker for these diseases and may be useful in the diagnosis and treatment of these conditions.

BRD1 has been shown to be overexpressed in many types of cancer, including breast cancer. This suggests that it may be a useful target for cancer therapies. For example, inhibitors of BRD1 have been shown to have anti-tumor effects in cell cultures and animal models of breast cancer.

In addition to its potential as a drug target, BRD1 is also a potential biomarker for breast cancer. The protein is often overexpressed in breast tissue samples from patients with breast cancer, and it has been shown to be associated with poor prognosis in these patients. By targeting BRD1, researchers may be able to develop new diagnostic tests or treatments for breast cancer.

BRD1 has also been implicated in the development of neurodegenerative diseases, including Alzheimer's disease. This suggests that it may be a useful target for therapies aimed at treating these conditions.

In addition to its potential as a drug target or biomarker, BRD1 is also of interest to researchers as a potential therapeutic target for a variety of diseases. Studies are being conducted to investigate the effects of inhibitors of BRD1 on a variety of cellular processes, including cell adhesion, migration, and angiogenesis.

In conclusion, BRD1 is a gene that encodes a protein that has been implicated in the development and progression of many diseases, including breast cancer. As a potential drug target and biomarker, BRD1 is a promising target for researchers to investigate the effects of inhibitors on cellular processes and to develop new treatments for these diseases. Further studies are needed to fully understand the role of BRD1 in disease and to develop effective therapies.

Protein Name: Bromodomain Containing 1

Functions: Scaffold subunit of various histone acetyltransferase (HAT) complexes, such as the MOZ/MORF and HBO1 complexes, that acts as a regulator of hematopoiesis (PubMed:16387653, PubMed:21753189, PubMed:21880731). Plays a key role in HBO1 complex by directing KAT7/HBO1 specificity towards histone H3 'Lys-14' acetylation (H3K14ac), thereby promoting erythroid differentiation (PubMed:21753189)

More Common Targets